Provided by Tiger Trade Technology Pte. Ltd.

Biogen

184.12
+0.48000.26%
Volume:100.53K
Turnover:18.44M
Market Cap:27.01B
PE:20.95
High:184.41
Open:182.63
Low:180.33
Close:183.64
52wk High:202.41
52wk Low:110.04
Shares:146.70M
Float Shares:146.23M
Volume Ratio:0.36
T/O Rate:0.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):8.79
EPS(LYR):8.79
ROE:7.39%
ROA:6.14%
PB:1.48
PE(LYR):20.95

Loading ...

Biogen Is Maintained at Neutral by Wedbush

Dow Jones
·
Feb 10

Biogen Refocuses On High-Need Neurology As New Drugs Reach Inflection Point

Simply Wall St.
·
Feb 10

Biogen Inc. Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
Feb 10

Biogen Sales Execution, Growth Support Long-Term EPS, RBC Says

MT Newswires Live
·
Feb 10

Biogen Posts Q4 Beat, Analysts Raise Price Targets On 'Significant Pipeline Diversification'

Benzinga_recent_news
·
Feb 09

Biogen Analysts Boost Their Forecasts After Upbeat Q4 Earnings

Benzinga
·
Feb 09

Biogen : Wedbush Raises Target Price to $187 From $178

THOMSON REUTERS
·
Feb 09

Biogen : Truist Securities Raises Target Price to $193 From $190

THOMSON REUTERS
·
Feb 09

Piper Sandler Adjusts Price Target on Biogen to $177 From $157, Maintains Neutral Rating

MT Newswires Live
·
Feb 09

Biogen, Inc : H.c. Wainwright Raises Target Price to $228 From $194

THOMSON REUTERS
·
Feb 09

Biogen Is Maintained at Neutral by Piper Sandler

Dow Jones
·
Feb 09

BUZZ-Street View: Spotlight turns to Biogen's pipeline

Reuters
·
Feb 09

U.S. RESEARCH ROUNDUP-Align Technology, Biogen, Citigroup

Reuters
·
Feb 09

China prüft Biogens Antrag auf subkutane LEQEMBI-Formulierung im beschleunigten Verfahren

Reuters
·
Feb 09

BRIEF-Biogen Says Biologics License Application For Subcutaneous Formulation Of Leqembi For Treatment Of Early Alzheimer’S Disease Designated For Priority Review In China

Reuters
·
Feb 09

Biogen: Biologics License Application for Subcutaneous Formulation of Leqembi for Treatment of Early Alzheimer’s Disease Designated for Priority Review in China

THOMSON REUTERS
·
Feb 09

Biogen: Undervalued Cash Flows and Growing Leqembi Franchise Support Raised Price Target and Buy Rating

TIPRANKS
·
Feb 09

Biogen price target raised to $200 from $190 at Wells Fargo

TIPRANKS
·
Feb 09

Biogen price target raised to $190 from $156 at Morgan Stanley

TIPRANKS
·
Feb 09

Biogen price target raised to $215 from $185 at Citi

TIPRANKS
·
Feb 09